BioCentury
ARTICLE | Clinical News

Galapagos' GLPG1690 improves FVC in Phase IIa for IPF

August 11, 2017 3:44 PM UTC

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported top-line data from the Phase IIa FLORA trial in 23 patients with idiopathic pulmonary fibrosis (IPF) showing that once-daily 600 mg oral GLPG1690 increased mean forced vital capacity (FVC) from baseline to week 12 by 8 mL vs. a reduction of 87 mL for placebo. The company also said GLPG1690 led to "more sensitive functional respiratory imaging (FRI) confirmed disease stabilization" compared to disease progression in the placebo arm. GLPG1690 was generally well tolerated.

Patients in the double-blind, Ukrainian and U.K. trial who were receiving IPF drugs Ofev nintedanib or Esbriet pirfenidone were required to discontinue treatment ≥4 weeks prior to receiving GLPG1690. The trial's primary endpoints are safety and pharmacokinetics. Secondary endpoints include pulmonary function function, biomarkers and quality of life (QOL)...

BCIQ Company Profiles

Galapagos N.V.

BCIQ Target Profiles

Autotaxin (ENPP2) (ATX)